Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Gennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, Maddalena Marchesi, Tanya Simuni, Kenneth Marek, Ronald B Postuma, Nicola Pavese, Fabrizio Stocchi, Jean-Philippe Azulay, Brit Mollenhauer, Lydia López-Manzanares, David S Russell, James T Boyd, Anthony P Nicholas, María R Luquin, Robert A Hauser, Thomas Gasser, Werner Poewe, Benedicte Ricci, Anne Boulay, Annamarie Vogt, Frank G Boess, Juergen Dukart, Giulia D'Urso, Rebecca Finch, Stefano Zanigni, Annabelle Monnet, Nathalie Pross, Andrea Hahn, Hanno Svoboda, Markus Britschgi, Florian Lipsmeier, Ekaterina Volkova-Volkmar, Michael Lindemann, Sebastian Dziadek, Štefan Holiga, Daria Rukina, Thomas Kustermann, Geoffrey A Kerchner, Paulo Fontoura, Daniel Umbricht, Rachelle Doody, Tania Nikolcheva, Azad Bonni
The New England journal of medicine 2022;387(5):421-432